메뉴 건너뛰기




Volumn 7, Issue 4, 2001, Pages 216-222

Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation

Author keywords

Autologous transplantation; Cytotoxicity; Immunotherapy; NK T cells; T cells

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD56 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DEXAMETHASONE; ETOPOSIDE; GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

EID: 0035031130     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11349808     Document Type: Article
Times cited : (86)

References (31)
  • 1
    • 0028790440 scopus 로고
    • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
    • Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
    • (1995) N Engl J Med. , vol.333 , pp. 1540-1545
    • Philip, T.1    Guglielmi, C.2    Hagenbeek, A.3
  • 2
    • 8944220233 scopus 로고    scopus 로고
    • A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
    • Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
    • (1996) N Engl J Med. , vol.335 , pp. 91-97
    • Attal, M.1    Harousseau, J.L.2    Stoppa, A.M.3
  • 3
    • 2942712161 scopus 로고    scopus 로고
    • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
    • Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
    • (1997) J Clin Oncol. , vol.15 , pp. 433-444
    • Collins, R.H.1    Shpilberg, O.2    Drobyski, W.R.3
  • 4
    • 0027509704 scopus 로고
    • Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukemia following allogeneic BMT
    • Szer J, Grigg AP, Phillips GL, Sheridan WP. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukemia following allogeneic BMT. Bone Marrow Transplant. 1993;11:109-111.
    • (1993) Bone Marrow Transplant. , vol.11 , pp. 109-111
    • Szer, J.1    Grigg, A.P.2    Phillips, G.L.3    Sheridan, W.P.4
  • 5
    • 0032992942 scopus 로고    scopus 로고
    • Reinventing bone marrow transplantation: Reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy
    • Champlin R, Khouri I, Kornblau S, et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Current Opinion Oncol. 1999;11:87-95.
    • (1999) Current Opinion Oncol. , vol.11 , pp. 87-95
    • Champlin, R.1    Khouri, I.2    Kornblau, S.3
  • 6
    • 0031879197 scopus 로고    scopus 로고
    • Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
    • Khouri IF, Keating M, Körbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
    • (1998) J Clin Oncol. , vol.16 , pp. 2817-2824
    • Khouri, I.F.1    Keating, M.2    Körbling, M.3
  • 7
    • 0022349817 scopus 로고
    • Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
    • Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485-1492.
    • (1985) N Engl J Med. , vol.313 , pp. 1485-1492
    • Rosenberg, S.A.1    Lotze, M.T.2    Muul, L.M.3
  • 8
    • 0023115642 scopus 로고
    • A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
    • Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889-897.
    • (1987) N Engl J Med. , vol.316 , pp. 889-897
    • Rosenberg, S.A.1    Lotze, M.T.2    Muul, L.M.3
  • 9
    • 0027529476 scopus 로고
    • Prospective randomized trial of high-dose interleukin-2 alone or in conjugation with lymphokine-activated killer cells for the treatment of patients with advanced cancer
    • Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjugation with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85:622-632.
    • (1993) J Natl Cancer Inst. , vol.85 , pp. 622-632
    • Rosenberg, S.A.1    Lotze, M.T.2    Yang, J.C.3
  • 10
    • 0025824067 scopus 로고
    • + cells: Examination of morphology, functions, T-cell receptor rearrangement, and poreforming protein expression
    • + cells: examination of morphology, functions, T-cell receptor rearrangement, and poreforming protein expression. Cell Immunol. 1991;136:486-495.
    • (1991) Cell Immunol. , vol.136 , pp. 486-495
    • Ortaldo, J.R.1    Winkler-Pickett, R.T.2    Yagita, H.3    Young, H.A.4
  • 11
    • 0022535970 scopus 로고
    • A subset of natural killer cells in peripheral blood displays a mature T cell phenotype
    • Schmidt RE, Murray C, Daley JF, et al. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med. 1986;164:351-356.
    • (1986) J Exp Med. , vol.164 , pp. 351-356
    • Schmidt, R.E.1    Murray, C.2    Daley, J.F.3
  • 12
    • 0022589079 scopus 로고
    • The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes
    • Lanier LL, Le AM, Civin CI, et al. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986;136:4480-4486.
    • (1986) J Immunol. , vol.136 , pp. 4480-4486
    • Lanier, L.L.1    Le, A.M.2    Civin, C.I.3
  • 13
    • 0028103808 scopus 로고
    • + cells derived from T-cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency
    • + cells derived from T-cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687-1696.
    • (1994) J Immunol. , vol.153 , pp. 1687-1696
    • Lu, P.H.1    Negrin, R.S.2
  • 14
    • 0025856106 scopus 로고
    • Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity
    • Schmidt-Wolf IGH, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139-149.
    • (1991) J Exp Med. , vol.174 , pp. 139-149
    • Schmidt-Wolf, I.G.H.1    Negrin, R.S.2    Kiem, H.P.3
  • 16
    • 0028917966 scopus 로고
    • Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia
    • Scheffold C, Brandt K, Johnston V, et al. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant. 1995; 15:33-39.
    • (1995) Bone Marrow Transplant. , vol.15 , pp. 33-39
    • Scheffold, C.1    Brandt, K.2    Johnston, V.3
  • 17
    • 0032211175 scopus 로고    scopus 로고
    • + cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice
    • + cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998;92:3318-3327.
    • (1998) Blood , vol.92 , pp. 3318-3327
    • Hoyle, C.1    Bangs, C.D.2    Pearl, C.3
  • 18
    • 0032693955 scopus 로고    scopus 로고
    • Visualizing the kinetics of tumor-cell clearance in living animals
    • Sweeney TJ, Mailänder V, Tucker AA, et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A. 1999;96:12044-12049.
    • (1999) Proc Natl Acad Sci U S A , vol.96 , pp. 12044-12049
    • Sweeney, T.J.1    Mailänder, V.2    Tucker, A.A.3
  • 19
    • 0031205120 scopus 로고    scopus 로고
    • Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation
    • Lu PH, Negrin RS. Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 1997;3:113-121.
    • (1997) Biol Blood Marrow Transplant. , vol.3 , pp. 113-121
    • Lu, P.H.1    Negrin, R.S.2
  • 20
    • 0032170052 scopus 로고    scopus 로고
    • Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation
    • Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood. 1998;92:1471-1490.
    • (1998) Blood , vol.92 , pp. 1471-1490
    • Guillaume, T.1    Rubinstein, D.B.2    Symann, M.3
  • 21
    • 0028089348 scopus 로고
    • Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation
    • Neubauer MA, Benyunes MC, Thompson JA, et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1994;13:311-316.
    • (1994) Bone Marrow Transplant. , vol.13 , pp. 311-316
    • Neubauer, M.A.1    Benyunes, M.C.2    Thompson, J.A.3
  • 22
    • 0026657518 scopus 로고
    • Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors
    • Bosly A, Guillaume T, Brice P, et al. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. Exp Hematol. 1992;20:962-968.
    • (1992) Exp Hematol. , vol.20 , pp. 962-968
    • Bosly, A.1    Guillaume, T.2    Brice, P.3
  • 23
    • 0029099188 scopus 로고
    • Immunotherapy with interleukin-2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: A feasibility trial
    • Benyunes MC, Higuchi C, York A, et al. Immunotherapy with interleukin-2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant. 1995;16:283-288.
    • (1995) Bone Marrow Transplant. , vol.16 , pp. 283-288
    • Benyunes, M.C.1    Higuchi, C.2    York, A.3
  • 24
    • 0028301366 scopus 로고
    • Propagation of large numbers of T cells with natural killer cell markers
    • Schmidt-Wolf IGH, Lefterova P, Johnston, et al. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol. 1994;87:453-458.
    • (1994) Br J Haematol. , vol.87 , pp. 453-458
    • Schmidt-Wolf, I.G.H.1    Lefterova, P.2    Johnston3
  • 25
    • 0028340717 scopus 로고
    • G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization, and composition of the graft
    • Dreger P, Haferlach T, Eckstein V, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol. 1994;87:609-613.
    • (1994) Br J Haematol. , vol.87 , pp. 609-613
    • Dreger, P.1    Haferlach, T.2    Eckstein, V.3
  • 26
    • 0028843985 scopus 로고
    • Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
    • Pan L, Delmonte J, Jalonen CK, Ferrara JLM. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood. 1995;86:4422-4429.
    • (1995) Blood , vol.86 , pp. 4422-4429
    • Pan, L.1    Delmonte, J.2    Jalonen, C.K.3    Ferrara, J.L.M.4
  • 27
    • 0032717657 scopus 로고    scopus 로고
    • Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions
    • Hartung T, Doecke WD, Bundschuh D, et al. Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. Clin Pharmacol Ther. 1999;66:415-424.
    • (1999) Clin Pharmacol Ther. , vol.66 , pp. 415-424
    • Hartung, T.1    Doecke, W.D.2    Bundschuh, D.3
  • 28
    • 0032864809 scopus 로고    scopus 로고
    • Recombinant human granulocyte colony-stimulating factor (rHuG-CSF): Effects on lymphocyte phenotype and function
    • Rutella S, Rumi C, Sica S, Leone G. Recombinant human granulocyte colony-stimulating factor (rHuG-CSF): effects on lymphocyte phenotype and function. J Interferon Cytokine Res. 1999;19: 989-994.
    • (1999) J Interferon Cytokine Res. , vol.19 , pp. 989-994
    • Rutella, S.1    Rumi, C.2    Sica, S.3    Leone, G.4
  • 29
    • 0032921767 scopus 로고    scopus 로고
    • Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response
    • Reyes E, Garcia-Castro I, Esquivel F, et al. Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response. Br J Cancer. 1999;80:229-235.
    • (1999) Br J Cancer , vol.80 , pp. 229-235
    • Reyes, E.1    Garcia-Castro, I.2    Esquivel, F.3
  • 30
    • 0003284325 scopus 로고    scopus 로고
    • Autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
    • Leemhuis T, Wells S, Scheffold C, et al. Autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma [abstract 3624]. Blood. 2000;96(suppl 1a):839a.
    • (2000) Blood , vol.96 , Issue.SUPPL. 1A
    • Leemhuis, T.1    Wells, S.2    Scheffold, C.3
  • 31
    • 85112358540 scopus 로고    scopus 로고
    • Generation of cytokine-induced killer cells (CIK) from leukemic samples and its in vitro cytotoxicity against autologous leukemia
    • Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells (CIK) from leukemic samples and its in vitro cytotoxicity against autologous leukemia [abstract 3841]. Blood. 2000; 96(suppl 1b):41b.
    • (2000) Blood , vol.96 , Issue.SUPPL. 1B
    • Linn, Y.C.1    Lau, L.C.2    Hui, K.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.